Sino Biopharmaceutical co-led the oncology treatment developer's latest round, in which it raised over $91m in funding.
Treadwell Therapeutics, US-based small molecule cancer therapy developer exploiting research from University Health Network, has secured more than $91m in a series B round co-led by pharmaceutical firm Sino Biopharmaceutical with investment adviser 3W Fund Management.
The round also featured venture creation firm Tio Bioventures, Prosperous Alliance, Alpha Win Capital, Fortune Ocean Growth Fund, private investor Adrian Cheng and unnamed others.
Spun out of Tio Bioventure’s drug discovery incubator, Treadwell is developing drugs that inhibit enzyme pathways to treat solid and blood cancers, using technology from Canadian research hospital.
The capital will be used to advance a drug pipeline that includes potential treatments for advanced solid tumours (CFI-402411) and leukaemia (CFI-400945) through preclinical and clinical development.
The startup also intends to submit an investigation new drug application for its CFI-402257 breast cancer candidate by the end of 2021. It had previously raised $27m in seed funding from Tio Bioventures…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
